A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Gastroparesis is a recognised complication of diabetes (both type 1 and type 2) and, whilst not the most commonly observed complication, it carries with it a significant impact on a person’s health, glycaemic control, social functioning and mental wellbeing. Gastroparesis is often not well recognised because of the disparate group of symptoms it may present with. Symptoms are often misattributed or not recognised, and consequently the diagnosis is either missed or delayed. It should be managed by a multidisciplinary team with knowledge of and expertise in this area. Above all, the team should be understanding and help steer patients to the best supportive care.
Author: Simon Saunders,
Clinical Lead Academic Consultant in Diabetes and Endocrinology, Mersey and West Lancashire Teaching Hospitals NHS Trust
Citation: Saunders S (2023) At a glance factsheet: Diabetic gastroparesis. Diabetes & Primary Care 25: [Early view publication]
Neil Baker and Isam Osman
An unusually good blood supply and peripheral neuropathy are reportedly accepted prerequisites for the pathogenesis of Charcot neuroarthropathy (CN) in people with diabetes. There is anecdotal evidence that CN does not occur in the presence of peripheral vascular disease. We report the first case of a person with diabetes who had revascularisation surgery performed to both legs independently, which was subsequently followed by CN in the corresponding feet. This case illustrates the importance of a good blood supply in the development of CN. Furthermore, it supports the concept that reduced arterial supply is protective against the development of CN. This case also highlights the need for regular follow-up reviews where postoperative hyperaemia is evident.
Citation: Baker N, Osman I (2023) Bilateral Charcot neuroarthropathy following successive surgical arterial revascularisation to both legs in a patient with diabetes — an interesting case history. The Diabetic Foot Journal 26(1): 36–9
Article points
1. A very good blood flow is a prerequisite for active Charcot development
2. Although this is a rare case, it is advised to be vigilant in monitoring a hot, swollen, inflamed foot and leg after vascular intervention in a patient with existing neuropathy
3. Early detection and immobilisation (cast) of active Charcot with regular follow up is imperative to facilitate optimal resolution and reduction in deformity
4. Differential diagnosis is essential in the presentation of a neuropathic red/ discoloured (dark), hot, swollen foot and leg, particularly if ulceration is present.
Authors
Neil Baker is Consultant Diabetes /Vascular Podiatrist, Sana Clinic Al Shaab Kuwait; formerly Ipswich Hospital NHS Trust; Isam Osman is Consultant Vascular Surgeon, King Saud Medical City, Riyadh, Saudi Arabia; formerly Ipswich Hospital NHS Trust;
Key words
- Charcot
- Neuropathy
- Peripheral arterial disease
- Vascular intervention
Metabolic changes that occur during menopause are associated with increased incidence of type 2 diabetes and its risk factors, while menopausal symptoms have a negative effect on a person’s day-to-day life, and consequently their diabetes self-management. In women who are going through menopause, effective hormone replacement therapy (HRT) can improve a wide array of cardiometabolic risk factors as well as the risk of new-onset type 2 diabetes. This factsheet covers the relationship between menopause and type 2 diabetes and provides recommendations on optimising HRT in women with diabetes.
Author: Claire Partridge, RGN, MSc Health Sciences (Diabetes)
Citation: Partridge C (2023) At a glance factsheet: Diabetes and menopause. Diabetes & Primary Care 25: [Early view publication]
Patients with venous leg ulcers (VLUs) experience a wide range of physical and psychosocial issues. This paper focuses on the impact of the sequelae of VLUs and the interventions that can be used to minimise that impact on patient wellbeing. VLU-related issues are described, such as high exudation with risk of leakage, soiling of clothing and bed linens, and the embarrassment this can cause. This also leads to the need for more frequent dressing changes, and potential dressing-related trauma associated with pain, stress and anxiety. Finally, dressing characteristics that should be considered in order to address these issues and improve the quality of life of patients with VLUs are discussed.
Authors:
Dot Weir and Phil Davies
Dot Weir is Wound Clinician, Saratoga Hospital Center for Wound Healing and Hyperbaric Medicine, Saratoga Springs, New York, US;
Phil Davies is Senior Global Medical Affairs Manager, Medical and Economic Affairs, Mölnlycke Health Care, Gothenburg, Sweden
Margaret Doucette and Stephanie Seabolt
Margaret Doucette is Associate Chief of Staff for Research at Boise VA Medical Center and Medical Director for the Wound/High Risk Foot/ Amputee Program. Clinical Associate Professor Univ of Washington, US;
Stephanie Seabright is Registered Nurse Clinical Research Coordinator at the Boise VA Medical Center working in wound/high risk foot clinic and Masters of Science in Nursing graduate student at Western Governor’s University, US Am putation of a lower extremity can be devastating, debilitating and demoralising, or it can be a successful, beneficial, definitive end point to a nonhealing diabetic foot ulcer (DFU). The decisionmaking process of if, and when, to amputate begins at the first patient visit and should be incorporated into the patient discussion early on for all high-risk patients. While prevention of amputation is most commonly the goal, early identification of risk factors and risk stratification can help design a realistic care plan, compassionately inform patient expectations and steward resource allocation. These 10 top tips will help guide you with the plan of care.
Chronic wounds are becoming of public health concern, and despite extensive literature supporting the use of electrotherapy in the management of chronic wounds, Nigerian physiotherapists are rarely involved in wound care. This study sought to determine physiotherapists’ knowledge and use of electrotherapy in wound management. It used a self-administered questionnaire to collect information from physiotherapists in various practice settings. It was found that the majority of respondents (98.7%) had a good understanding of the role of electrotherapy in wound care, but had a poor understanding of both precaution (10.2%) and wound assessment (7.9%). Only 11.8% of physiotherapists were found to be involved in wound care and there was no association between knowledge and job rank (P =0.27).
Author:
Chioma Lynn Onuchukwu
Chioma Lynn Onuchukwu is Chief Physiotherapist, Enugu State University Teaching Hospital, Enugu, Nigeria
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。